Caitlin McMahon
Foundation Medicine
10 Papers
56 Citations
Caitlin McMahon is an academic researcher from Foundation Medicine. The author has contributed to research in topics: Targeted therapy & Lung cancer. The author has an hindex of 6, co-authored 10 publications.
Chat about Author
Papers
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
Garrett M. Frampton,Siraj M. Ali,Margaret Rosenzweig,Juliann Chmielecki,Xinyuan Lu,Todd M. Bauer,Mikhail Akimov,Jose A. Bufill,Carrie B. Lee,David Jentz,Rick Hoover,Sai-Hong Ignatius Ou,Ravi Salgia,Tim Brennan,Zachary R. Chalmers,Savina Jaeger,Alan Huang,Julia A. Elvin,Rachel L. Erlich,Alex Fichtenholtz,Kyle Gowen,Joel R. Greenbowe,Adrienne Johnson,Depinder Khaira,Caitlin McMahon,Eric M. Sanford,Steven Roels,Jared White,Joel Greshock,Robert Schlegel,Doron Lipson,Roman Yelensky,Deborah Morosini,Jeffrey S. Ross,Eric A. Collisson,Malte Peters,Philip J. Stephens,Vincent A. Miller +37 more
TL;DR: Analysis of tumor genomic profiles from 38,028 patients is reported to identify 221 cases with METex14 mutations, including 126 distinct sequence variants, and identify a unique subset of patients likely to derive benefit from MET inhibitors.
749
STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
Vivek Subbiah,Caitlin McMahon,Shreyaskumar Patel,Ralph Zinner,Elvio G. Silva,Julia A. Elvin,Ishwaria Mohan Subbiah,Chimela Ohaji,Dhakshinamoorthy Ganeshan,Deepa Anand,Charles F Levenback,Jenny Berry,Tim Brennan,Juliann Chmielecki,Zachary R. Chalmers,John Mayfield,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross,Siraj M. Ali +19 more
TL;DR: This case represents the first report of clinical response to targeted therapy in a tumor harboring a DCTN1-ALK fusion protein, and can identify clinical relevant genomic alterations that both direct treatment targeted therapy and help discriminate between similar diagnostic entities.
A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling.
Evgeny Yakirevich,Siraj M. Ali,Anthony Mega,Caitlin McMahon,Alexander S. Brodsky,Jeffrey S. Ross,Justin M. Allen,Julia A. Elvin,Howard Safran,Murray B. Resnick +9 more
TL;DR: This is the first report that identifies SDHA inactivation in RCC, and it is confirmed that the homozygous deletion led to the loss of SDHA and SDHB protein expression.
61
A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy.
C Williams,Caitlin McMahon,Siraj M. Ali,Mark Abramovitz,Kirstin Williams,Jessica Klein,Heidi McKean,Roman Yelensky,Thomas J. George,Julia A. Elvin,Salil Soman,Doron Lipson,Juliann Chmielecki,Deborah Morosini,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross,Brian Leyland-Jones +17 more
TL;DR: Combination therapy of dabrafenib and trametinib with standard cytotoxic chemotherapy resulted in a durable major ongoing response for the patient, illustrating the utility of comprehensive genomic profiling with personalized targeted therapy for aggressive metastatic colorectal adenocarcinomas.